All News

Aug 24, 2009

Flexible Stenting Solutions Inc. and Micrus Endovascular Sign Licensing and Development Agreement for Flow Diversion Technology

SAN JOSE, Calif.--(BUSINESS WIRE)--Micrus Endovascular Corporation (Nasdaq: MEND - News) and privately held Flexible Stenting Solutions Inc. of Eatontown, N.J., today announced the signing of an exclusive agreement to jointly develop a flow diversion technology for neurovascular indicati Read More...

Filed Under: GBP Captial News

Jun 25, 2009

Lentigen Collaborator Case Western Reserve University Receives $5M From Third Frontier Commission for the Center for Stem Cell & Regenerative Medicine

CLEVELAND, June 25 /PRNewswire-USNewswire/ -- The Center for Stem Cell & Regenerative Medicine (CSCRM), comprised of Case Western Reserve University (CWRU), Cleveland Clinic (CC), University Hospitals (UH), and Athersys, Inc. has received $5 million from Ohio's Third Frontier Commission Read More...

Filed Under: Company News

Feb 04, 2009

Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement

GAITHERSBURG, Md. and ATLANTA, Feb 4 -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, and Expression Therapeutics, a biotechnology company specializing in factor VIII-based therapeutics, today announced Read More...

Filed Under: Company News

Jan 21, 2009

Flexible Stenting Solutions, Inc. Receives CE Mark for New FlexStent Femoropopliteal Self Expanding Stent System

EATONTOWN, N.J. - January 21, 2009 - Flexible Stenting Solutions, Inc. ("FSS"), a leading developer of next-generation flexible stents, announced today it has received CE Mark (Conformite Europeene) for its FlexStent™ Femoropopliteal Self Expanding Stent System. Stent sizes include a complet Read More...

Filed Under: Company News

Dec 16, 2008

MabVax Therapeutics Receives Two Small Business Technology Transfer Program Awards From The National Cancer Institute

San Diego, CA, December 16, 2008 -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, announced the company has received two grant awards from t Read More...

Filed Under: Company News

Dec 04, 2008

Lentigen and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza

Seattle, WA and Gaithersburg, MD, December 4, 2008—The biotech company Lentigen Corporation and the nonprofit global health organization PATH announced today a partnership to accelerate research on a pandemic influenza vaccine. PATH will initially invest $3 million over 27 months and wo Read More...

Filed Under: Company News

Oct 01, 2008

Lentigen Corporation and the United States Army Agree to Contract

GAITHERSBURG, Md., Oct 01, 2008 /PRNewswire via COMTEX/ -- Lentigen Corporation announced today that it has established a contract with the United States Army to extend the programs established in the initial agreement announced in 2006. This contract is for a further phase of Lentigen Corpor Read More...

Filed Under: Company News

Aug 14, 2008

Flexible Stenting Solutions Announces Successful Completion of First-in-Man Study of Third Generation Peripheral Arterial Stent

Eatontown , NJ - Flexible Stenting Solutions Inc., a leading developer of third generation peripheral arterial stents, announced today that a physician at Auckland City Hospital in New Zealand successfully implanted several of its third generation arteria Read More...

Filed Under: Company News

Aug 12, 2008

MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research

San Diego, CA, August 12, 2008 -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, today announced the completion of two separate licensing Read More...

Filed Under: Company News

Aug 04, 2008

Lentigen, Invitrogen to Provide Lentivirus Products and Services for Gene Over-Expression

CARLSBAD, Calif. & BALTIMORE-- Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and Lentigen Corporation, a privately-held biotechnology company specializing in the development and manufacture of lentivira Read More...

Filed Under: Company News

57 results:

<<12345...6>>